23andMe, the genetic testing company, just announced that it will be entering a 4-year partnership with pharmaceutical giant GlaxoSmithKline (GSK) to develop new drugs and therapies.

As part of the partnership, 23andMe will share voluntarily-shared genetic data with the big pharma company. Maria Liu from First Health Advisory Solutions joined us to talk about the security concerns and potential worries that come with companies sharing medical data.

For the latest news, videos, and podcasts in the Healthcare Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!
Twitter – @HealthMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale